Paul M. Bisaro

Paul Bisaro is an experienced global business leader with almost 30 years of pharmaceutical experience and has a track record of driving company growth through operational execution and corporate transformation. He has served as Chief Executive Officer as well as Executive Chairman of numerous companies including Watson Pharmaceuticals, Actavis plc, Allergan plc, Impax Laboratories and Amneal Pharmaceuticals. Mr. Bisaro also served as Chief Operations Officer and General Counsel of Barr Laboratories.

In addition to his service on the Board of Myriad, Mr. Bisaro serves as Chairman of the Board of Mallinckrodt, PLC and is currently on the Board of Zoetis, Inc. (NYSE:ZTS) and TherapeuticsMD (NASDAQ:TXMD). Since 2014, Mr. Bisaro has been a Member of the Board of Visitors of the Catholic University of America’s Columbus School of Law. He also served as Chairman of the Board of the Generic Pharmaceutical Association (GPhA, now the Association of Accessible Medicines) in 2010 and 2011. Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan (1983) and a Juris Doctor from Catholic University of America in Washington, D.C. (1989).